AGN-232411
DrugAGN-232411 topical ophthalmic solution
NCT Number: NCT02420730
This study will examine the safety, tolerability, and systemic pharmacokinetics of up to 3 different concentrations of AGN-232411 topical ophthalmic solution in healthy participants and participants with dry eye.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Sall Research Center, Artesia, California, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Stage 1
-Healthy participants.
Stage 2 -Participants with the symptoms of dry eye disease.
Exclusion criteria
Stage 1
-Known allergies or sensitivities to study medications, fluorescein, or lissamine green
Stage 2
AGN-232411 topical ophthalmic solution
Vehicle for AGN-232411 topical ophthalmic solution.
Time frame: Up to 56 days
Allergan
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05447078
Healthy Volunteers, Infections
Jackson, Mississippi, United States
View Trial DetailsNCT07513532
Healthy Volunteers
Seattle, Washington, United States
View Trial DetailsNCT07090655
Healthy Volunteers
Brisbane, Australia
View Trial DetailsNCT01915212
Communicable Diseases, DNA Virus Infections
Bethesda, Maryland, United States
View Trial Details